Progyny's Selling Season Surge: Fertility Benefits Ride the Cost-Cutting Wave
Strong Q2 results and a bright selling season outlook signal that employers' GLP-1-driven cost pain is becoming Progyny's gain.
PGNY · Earnings Call · 2026-08-06
The Quarter at a Glance
Progyny posted a record second quarter, with revenue up 5.3% reported and 11% ex the transition-of-care client, while gross margin expanded 180 basis points and adjusted EBITDA reached new highs. But the real story is the statement from CEO Peter Anevski: “We are seeing meaningful momentum in the market, and I think it would be useful to help you understand why we believe our solutions continue to resonate so strongly with employers.” — Peter Anevski, CEO · 2026-08-06 That momentum is not just about adding new logos; it's about winning large competitive conversions and doing so earlier than usual, as early commitments are pacing "meaningfully ahead" of last year.
Brownfield Wins and the GLP-1 Tailwind
The most interesting shift is the mix of new business. Management explicitly told analysts that “What we are seeing more of this year is more brownfield than greenfield.” — Peter Anevski, CEO · 2026-08-06 Employers are switching to Progyny from both VC-backed competitors and carrier-based solutions. The catalyst appears to be the need to control overall medical costs, particularly from GLP-1 therapies, which are driving up pharmacy spend and forcing employers to look for savings elsewhere. As Peter noted in the prepared remarks, “Employers are also experiencing high cost trends in their traditional medical and pharmacy coverage with increases of 10% or more projecting further increases next year.” — Peter Anevski, CEO · 2026-08-06 This cost environment is making fertility benefits a strategic lever—a high-value, low-utilization benefit that can bend the cost curve without the recurring expense of chronic medications.
The result is a surge in competitive displacement. A block quote from the Q&A captures the tone:
It is important to note that the reason only reason why I am calling it out is because it is more than what we have seen in the past. But we are getting all sorts of opportunities from Brownfield and some Greenfield as well.
This is a genuine inflection: the company is converting employers who already have a fertility benefit, and the win rates are improving.
Seasonality, Guidance, and a Conservative Mark
The quarter wasn't without a wrinkle. CFO Mark Livingston highlighted a slightly more pronounced summer seasonal slowdown, but he was quick to frame it as normal: “We view this to be the ordinary rhythm of activity and not an indication of a new macro trend or a change in the overall trajectory of engagement.” — Mark S. Livingston, CFO · 2026-08-06 The guidance for Q3 revenue of $335–345M reflects that caution, but management reiterated full-year growth of 9.7–11.7% ex the transition client, implying a second-half acceleration. This conservative posture is consistent with prior years—in May 2026, management noted that early commitments are often weighted to "not-nows" (“Regarding your first question, as always, early commitments-a higher proportion of them do come from not-nows.” — Peter Anevski, Chief Financial Officer · 2026-05-07), suggesting the pipeline is still building. The key difference this year is that the early wins are coming from larger, more valuable accounts.
Capital Returns and Balance Sheet Strength
Progyny's cash generation remains a standout. Operating cash flow exceeded $50M for the fourth time in five quarters, and the company has already repurchased 10.8M shares since November, reducing share count by ~12.5%. The new $200M authorization gives further buyback power. This financial flexibility is a direct result of margin expansion—gross margin reached 25.3%, up 1.9pp year-over-year, driven by operating leverage and lower stock comp. Gross margin is now at its highest level in the company's history, and the trend is still upward. With $237M in cash and no debt, the balance sheet is pristine, and management remains open to M&A or further buybacks.
The Stock's Re-rating Narrative
The market is taking notice. Over the past 90 days, PGNY has rallied ~57%, with a 96% move up in 12 weeks before a 19% pullback. The stock now trades at just 1.0x trailing revenue, down from a peak of 11.7x in 2021—a massive de-rating that reflects prior growth deceleration. But the strong selling season and the clear cost-control narrative are starting to re-rate the story. Management is also expanding into health plan partnerships and Progyny Select, which, while not material for 2027, extends the addressable market. The combination of accelerating competitive wins, pristine capital returns, and a discounted multiple makes this a compelling name in motion.
What Changed and Why It Matters
The core change is the competitive dynamic: Progyny is no longer just winning new adopters; it is displacing incumbents at a faster clip. The medical cost environment, exacerbated by GLP-1s, is pushing employers to seek proven cost savers, and Progyny's 10-year track record is the proof point. Early commitments are ahead, retention risk is largely removed, and the pipeline for 2027 includes jumbo opportunities. If the selling season closes as promised, the growth re-acceleration will be a meaningful step change from the transition-agreement hangover of 2025. Investors are starting to see it, and the tape reflects that optimism.